Nanobiotix Starts Clinical Trial with Lead Product NBTXR3
A Completely New Cancer Treatment to Be Tested in Patients with Soft Tissue Sarcoma
15-Sep-2011 -
Nanobiotix announced that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.27 patients diagnosed with soft tissue sarcoma will be enrolled in the Phase I study and will receive NBTXR3 as an intra-tumoral ...
cancer
clinical trials
phase I studies
+2